Nilsson Maria, Hägglöf Christina, Hammarsten Peter, Thysell Elin, Stattin Pär, Egevad Lars, Granfors Torvald, Jernberg Emma, Wikstrom Pernilla, Halin Bergström Sofia, Bergh Anders
Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Department of Surgical and Perioperative Sciences, Urology, Umeå University, Umeå, Sweden.
PLoS One. 2015 Oct 26;10(10):e0140985. doi: 10.1371/journal.pone.0140985. eCollection 2015.
Lysyl oxidase (LOX) has been shown to both promote and suppress tumor progression, but its role in prostate cancer is largely unknown. LOX immunoreactivity was scored in prostate tumor epithelium, tumor stroma and in the tumor-adjacent non-malignant prostate epithelium and stroma. LOX scores in tumor and non-malignant prostate tissues were then examined for possible associations with clinical characteristics and survival in a historical cohort of men that were diagnosed with prostate cancer at transurethral resection and followed by watchful waiting. Men with a low LOX score in the non-malignant prostate epithelium had significantly longer cancer specific survival than men with a high score. Furthermore, LOX score in non-malignant prostate epithelium remained prognostic in a multivariable analysis including Gleason score. LOX score in prostate tumor epithelium positively correlated to Gleason score and metastases but was not associated with cancer survival. LOX score in tumor and non-malignant prostate stroma appeared unrelated to these tumor characteristics. In radical prostatectomy specimens, LOX immune-staining corresponded to LOX in-situ hybridization and LOX mRNA levels were found to be similar between tumor and adjacent non-malignant areas, but significantly increased in bone metastases samples. LOX levels both in tumors and in the surrounding tumor-bearing organ are apparently related to prostate cancer aggressiveness.
赖氨酰氧化酶（LOX）已被证明既可以促进也可以抑制肿瘤进展，但其在前列腺癌中的作用在很大程度上尚不清楚。对前列腺肿瘤上皮、肿瘤基质以及肿瘤邻近的非恶性前列腺上皮和基质中的LOX免疫反应性进行评分。然后，在经尿道前列腺切除术中被诊断为前列腺癌并接受观察等待的男性历史队列中，检查肿瘤和非恶性前列腺组织中的LOX评分与临床特征和生存率之间的可能关联。非恶性前列腺上皮中LOX评分低的男性的癌症特异性生存期明显长于评分高的男性。此外，在包括Gleason评分在内的多变量分析中，非恶性前列腺上皮中的LOX评分仍然具有预后价值。前列腺肿瘤上皮中的LOX评分与Gleason评分和转移呈正相关，但与癌症生存率无关。肿瘤和非恶性前列腺基质中的LOX评分似乎与这些肿瘤特征无关。在根治性前列腺切除术标本中，LOX免疫染色与LOX原位杂交结果一致，并且发现肿瘤和相邻非恶性区域之间的LOX mRNA水平相似，但在骨转移样本中显著升高。肿瘤及其周围携带肿瘤器官中的LOX水平显然与前列腺癌的侵袭性有关。
